Fc-mediated Effector Functional Assays

The Importance of Fc-mediated Effector Function

Antibody medications have increasingly become the spotlight in worldwide pharmaceutical research and development because of their exclusive biological targeting benefits. The antigen binding section (Fab) of antibodies primarily identifies and latches onto antigens. Meanwhile, the crystalline subunit (Fc) is the point of interaction with effector molecules or cells, which in turn produces toxic effects. Consequently, the impact mediated by the Fc segment is a crucial part of the functioning of antibody drugs.

Fig. 1 The framework and functional mechanism of monoclonal antibodies.¹

Our Fc-mediated Effector Functional Assays

Various Fc-engineering strategies have been developed to enhance the anti-tumor potential of antibodies. These Fc-mediated effector functions play a crucial role in the therapeutic efficacy of most clinically approved antibodies. Creative Biolabs succeeds in developing a series of Fc-mediated effector functional assays to help customers evaluate the efficacy of therapeutic antibodies and discover more antibody-based compounds. Our Fc-mediated effector functional assays feature highly sensitive and extremely stable, which include the following:

ADCC Assay Creative Biolabs is well-equipped to handle a wide range of cell samples, ensuring that we can cater to our customers' specific requirements. Additionally, we offer a diverse selection of cell lines to meet various demands. Regarding the service modes, we offer extensive available assays, including but not limited to primary ADCC assay, and ADCC reporter bioassay. These strategies enable our customers to swiftly achieve their desired outcomes.	Fig. 2 ADCC assay.
ADCP Assay ADCP assay, a pivotal mechanism of antibody therapies, involves the phagocytosis of target cells by immune cells like monocytes, macrophages, neutrophils, and dendritic cells. The primary pathway for this process is through FcγRIIa (CD32a) on macrophages. Our comprehensive range of ADCP assays includes primary ADCP assay and ADCP reporter Assay, to meet the various needs of global customers.	Fig. 3 ADCP assay.
CDC Assay Complement-dependent cytotoxicity (CDC) is a process in which antibodies activate a cascade of complement-related reactions to lyse unwanted target cells. It is a mechanism commonly used by therapeutic antibodies to eliminate target cells. Creative Biolabs offers an integrated CDC assay platform that provides various options for cell types, complement sources, and assay endpoints.	Fig. 4 CDC assay.
FcγR Binding Assay Our FcγR binding assay is designed to investigate the binding interactions between antibody Fc regions and Fcγ receptors (FcγRs). In our assay, we not only supply a full range of binding services for FcγR targets (e.g., FcγR1/CD64, FcγR2a/CD32a (R/H variant), FcγR2b/CD32b, FcγR3a/CD16a (V/F variant), FcγR3b/CD16b) but also deliver diverse approaches for the analysis. With our assay, we can provide valuable insights into the functional properties of therapeutic antibodies and their potential for inducing indirect cytotoxicity.	Fig. 5 FcγR binding assay.
FcRn Binding Assay The FcRn (neonatal Fc receptor) has the ability to bind to and internalize serum antibodies at low pH (6.0) through pinocytosis. It then releases these antibodies at physiological pH (7.2) after recycling, thereby preventing their degradation in lysosomes. Creative Biolabs offers an efficient FcRn binding assay that can be used to estimate and predict the pharmacokinetic (PK) performance of therapeutic antibodies in vitro. By using our assay, global customers can benefit from real-time dynamic monitoring of antibody binding.	Fig. 6 FcRn binding assay.
C1q Binding Assay C1q is the main protein involved in binding to the Fc region of antibodies, and a high affinity for C1q is associated with enhanced complement-dependent cytotoxicity (CDC). At Creative Biolabs, we utilize cutting-edge surface plasmon resonance technology to conduct thorough kinetic analysis. With our state-of-the-art facilities and deep expertise in the field, our C1q binding assay serves as an excellent adjunct to cell-based CDC assays, providing valuable insights into the underlying mechanisms.	Fig. 7 C1q binding assay.
FcεR Binding Assay Creative Biolabs is committed to providing a variety of customized solutions for characterizing the binding properties of custom antibodies to FcεRs to boost customers' antibody research into the market.	Fig.8 Human Fc receptors for IgE (FcεR).2
Cell Line Development Service for Antibody Functional Verification Creative Biolabs widely provides a cutting-edge cell line development service for antibody functional verification to assist in customers' antibody development project. Taking advantage of numerous advanced technologies, we specialize in developing custom cell lines, including functional target cell lines and effector cell lines.	Fig. 9 The effector mechanisms of antibodies.3

Key Advantages

• A variety of high-quality antigens and Fc receptor proteins are free for customers to choose from.
• Professional and efficient research team.
• Stringent quality management control system in place.
• Customized program design and detailed report generation.

For more details about our Fc-mediated effector functional assays, please don't hesitate to contact us. Anticipating to receive your inquiry and order.

Reference

1. van der Horst, Hilma J., et al. "Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies." Cancers 12.10 (2020): 3041.
2. Geyer, Chiara Elisabeth, et al. "Physiological and pathological inflammation induced by antibodies and pentraxins." Cells 10.5 (2021): 1175.
3. Zahavi, David, and Louis Weiner. "Monoclonal antibodies in cancer therapy." Antibodies 9.3 (2020): 34.

For Research Use Only.